Post-earnings recap
Reported
Thu, Feb 4, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that Arrowhead Pharmaceuticals missed expectations on EPS, which is a concern for investors. However, the stock rose by 4.47%, likely driven by market optimism or other factors not directly related to the earnings results. The lack of revenue data and guidance may leave investors cautious about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | -120.04% |
| Revenue | N/A | N/A | N/A |
Management's tone was defensive, indicating awareness of current challenges. They emphasized their commitment to long-term strategies despite not providing specific guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges but remains focused on its long-term goals.